Suven Life Sciences completed enrollment of patients to the phase-2, Proof of Concept (PoC) clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
AI Assistant
Suven Life Sciences Ltd
2023
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.